1. Show article details.

    Onkos Surgical® partners with Integrum® to expand US market for the OPRA™ Implant System; a revolutionary osseointegration and bone-anchored prosthetic technology

    PR Newswire – 7:31 AM ET 01/21/2020

    PARSIPPANY, N.J., Jan. 21, 2020  Onkos Surgical, Inc. a leader in the field of musculoskeletal oncology and personalized orthopaedics announced today a multi-year agreement with Integrum AB. Patrick Treacy, co-founder and CEO stated, "We are delighted to partner with Dr. Brånemark and Integrum, global experts and leading pioneers in the field of osseointegration.

  2. Barnes upgraded to buy from neutral at UBS

    MarketWatch – 9:31 AM ET 01/15/2020
  3. Barnes upgraded to hold from sell at SunTrust RH

    MarketWatch – 8:16 AM ET 01/08/2020
  4. Show article details.

    BRIEF-Barnes Group Inc Sees Non-Cash, Pre-Tax Impairment Charge Of $12 Million In Q4

    Reuters – 8:00 AM ET 12/20/2019

    Barnes Group Inc (B): * Barnes Group Inc (B) - SEES NON-CASH, PRE-TAX IMPAIRMENT CHARGE OF $12 MILLION IN Q4 Source text: Further company coverage:

  5. Show article details.

    BRIEF-Barnes Group Inc Announces Agreement To Sell Its Seeger-Orbis Business To The Kajo Neukirchen Group

    Reuters – 7:51 AM ET 12/20/2019


  6. Show article details.

    Barnes Group Inc. Announces Agreement to Sell Its Seeger-Orbis Business to the Kajo Neukirchen Group

    Business Wire – 7:45 AM ET 12/20/2019

    Barnes Group Inc. (B), a global provider of highly engineered products, differentiated industrial technologies, and innovative solutions, today announced that it has entered into a definitive agreement to sell its Seeger-Orbis business to the Kajo Neukirchen Group.

  7. Show article details.

    BioArctic Announces Research Collaboration with Eisai Regarding BAN2401

    PR Newswire – 10:21 AM ET 12/17/2019

    STOCKHOLM, Dec. 17, 2019 BioArctic AB announced today the initiation of a research collaboration with Eisai aimed at further studying the unique profile of the investigational drug candidate BAN2401. The research collaboration with Eisai is in addition to the existing development and commercialization agreement for BAN2401.

  8. Show article details.

    Acoustic Simulation Advances Help Manufacturers Innovate to Cut Transport Noise

    PR Newswire – 5:46 AM ET 12/13/2019

    MONT-SAINT-GUIBERT, Belgium, Dec. 13, 2019 Free Field Technologies, part of Hexagon's Manufacturing Intelligence division, today announced the Actran 2020 suite comprising new acoustic, vibro-acoustic and aero-acoustic technologies that enable aerospace and automotive manufacturers to build more accurate noise production and optimization into their design processes.

  9. Show article details.

    BioArctic's Partner Eisai Presents Data from the Ongoing BAN2401 Phase 2b Extension Study in Early Alzheimer's Disease

    PR Newswire – 2:35 PM ET 12/05/2019

    STOCKHOLM, Dec. 5, 2019 BioArctic AB announced today that data from the ongoing BAN2401 Phase 2b open-label extension study in early Alzheimer's disease patients was presented by Eisai at the Clinical Trials in Alzheimer's Disease conference in San Diego, US. "This baseline open label extension study data is encouraging and supports the consistent benefits seen in the core Phase 2b study.

  10. Show article details.

    Barnes Group Inc. Announces Fourth Quarter and Full Year 2019 Earnings Conference Call and Webcast

    Business Wire – 1:30 PM ET 12/05/2019

    Barnes Group Inc. (B) today announced it will release fourth quarter and full year 2019 financial results on Friday, February 21, 2020, before the market opens. Barnes Group (B) will also host a conference call which will begin at 8:30 a.m. on that day to discuss the results and the Company’s outlook.

  11. Show article details.

    Barnes Group Inc. Names Stephen Moule Senior Vice President, Barnes Group Inc. and President, Barnes Industrial

    Business Wire – 9:05 AM ET 12/02/2019

    Barnes Group Inc. (B), a global provider of highly engineered products and differentiated industrial technologies, today announced the appointment of Stephen Moule, to the position of Senior Vice President, Barnes Group Inc. (B) and President, Barnes Industrial, effective immediately.

  12. Show article details.

    BioArctic and Eisai to Present Data on BAN2401 at the Clinical Trials on Alzheimer's Disease Conference

    PR Newswire – 2:17 AM ET 12/02/2019

    STOCKHOLM, Dec. 2, 2019 BioArctic AB announced today that presentations related to BAN2401 will be given at the 12th Clinical Trials on Alzheimer's Disease conference to be held December 4-7 in San Diego, California, USA. Data regarding amyloid levels at the beginning of the open label extension phase of the Phase 2b study in patients with early Alzheimer's disease will be presented by Eisai.

  13. Show article details.

    New Cradle Software Makes Complex Multi-physics Simulation Realistic for Anyone

    PR Newswire – 1:18 PM ET 11/21/2019

    OSAKA, Japan, Nov. 21, 2019  Cradle Software, part of Hexagon's Manufacturing Intelligence Division, today announced advanced new co-simulation and post-processing capabilities that make it easier for any engineer to analyse multi-physics problems and analyse mixed fluid-particle interactions.

  14. Show article details.

    Manatee County Selects Industry Leader Hexagon to Deploy Public Safety Systems in the Cloud

    PR Newswire – 9:00 AM ET 11/21/2019

    HUNTSVILLE, Ala. The project, expected to go live in 2020, will support all police, fire and EMS agencies by upgrading the county's computer-aided dispatch, mobile and analytics systems to SaaS deployments of HxGN OnCall solutions on Microsoft Azure.

  15. Show article details.

    New Generative Design Solution Cuts Additive Manufacturing Design Processes by Up to 80 Percent

    PR Newswire – 7:03 AM ET 11/20/2019

    FRANKFURT AM MAIN, Germany, Nov. 20, 2019 Formnext 2019 -- MSC Software Corporation, a global leader in computer-aided engineering simulation software and services, today announced MSC Apex Generative Design, a new design optimisation solution that improves quality through unparalleled automation of design processes with embedded manufacturing knowledge.

  16. Show article details.

    Markforged and MSC Software Partner to Provide Simulation and Performance Tools to Customers

    Business Wire – 5:30 AM ET 11/20/2019

    With this new partnership, manufacturers will validate the strength and capabilities of their 3D printed parts, opening up the technology for more applications across the manufacturing process Markforged, the leading provider of metal and carbon fiber 3D printers, and MSC Software Corporation, a global leader in computer-aided engineering simulation software and services, today announced a tech...

  17. Show article details.

    BioArctic Announces Results From Interim Analysis of the Phase 1/2 Study of SC0806 in Patients With Complete Spinal Cord Injury

    PR Newswire – 6:17 PM ET 11/18/2019

    STOCKHOLM, Nov. 18, 2019  BioArctic AB announced today the results of an interim analysis of a Phase 1/2 study of SC0806 in patients with complete spinal cord injury. BioArctic's treatment concept, SC0806, is a biodegradable medical device surgically implanted into the injured spinal cord with the goal to restore function.


Today's and Upcoming Events

  • Feb

    B to announce Q4 earnings (Confirmed)

Past Events (last 90 days)

  • Nov

    B ex-Dividend for $0.16 on 11/25/2019

    • Announce Date: 10/17/2019
    • Record Date: 11/26/2019
    • Pay Date: 12/10/2019
  • Oct

    B announced Q3 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.

Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

See the Latest Features
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.